Overview

Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This clinical trial is evaluating a drug called AC699 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer. The main goals of this study are to: - Identify the recommended dose of AC699 that can be given safely to participants - Evaluate the safety profile of AC699 - Evaluate the pharmacokinetics of AC699 - Evaluate the effectiveness of AC699
Phase:
Phase 1
Details
Lead Sponsor:
Accutar Biotechnology Inc